FORTE GROUP HOLDINGS INC.

# Signal Note: OrbiMed Initiates $32.6M Position in Vonteixra OrbiMed's entry into VNTXF signals confidence in Forte's clinical pipeline, likely driven by upcoming Phase 2/3 data readouts for its lead programs in rare hematologic and oncologic indications. The $32.6M position size (~1.2M shares) represents a meaningful commitment from one of healthcare's most selective institutional investors, typically indicating conviction around near-term catalysts or valuation inflection points. Monitor for clinical trial announcements and regulatory milestones in the next 6-12 months.